Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-26-002744
Filing Date
2026-05-15
Accepted
2026-05-15 17:22:14
Documents
66
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zk2635243.htm   iXBRL 10-Q 761046
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 8355
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 8086
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 5209
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 5017
  Complete submission text file 0001178913-26-002744.txt   6139152

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE slxn-20260331.xsd EX-101.SCH 131864
7 XBRL CALCULATION FILE slxn-20260331_cal.xml EX-101.CAL 29627
8 XBRL DEFINITION FILE slxn-20260331_def.xml EX-101.DEF 267074
9 XBRL LABEL FILE slxn-20260331_lab.xml EX-101.LAB 1382742
10 XBRL PRESENTATION FILE slxn-20260331_pre.xml EX-101.PRE 353963
70 EXTRACTED XBRL INSTANCE DOCUMENT zk2635243_htm.xml XML 541995
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42253 | Film No.: 26989846
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)